News Headlines Article

Supreme Court ruling carries implications for future drug patent cases
Modern Healthcare

The U.S. Supreme Court Tuesday vacated a lower court’s ruling that had ended patent protection for Teva Pharmaceuticals’ popular multiple sclerosis drug Copaxone. The decision could have broader implications for how courts decide future pharmaceutical patent disputes.The justices decided 7-2 to vacate a lower court’s ruling that the Jerusalem-based pharmaceutical company’s key patent on the drug was invalid.